CGEN
Price
$1.41
Change
-$0.02 (-1.41%)
Updated
Sep 4, 04:59 PM (EDT)
Capitalization
132.33M
63 days until earnings call
SPHRF
Price
$0.10
Change
+$0.02 (+25.00%)
Updated
Aug 26 closing price
Capitalization
35.44M
Interact to see
Advertisement

CGEN vs SPHRF

Header iconCGEN vs SPHRF Comparison
Open Charts CGEN vs SPHRFBanner chart's image
Compugen
Price$1.41
Change-$0.02 (-1.41%)
Volume$1.09K
Capitalization132.33M
Starpharma Holdings
Price$0.10
Change+$0.02 (+25.00%)
Volume$23.82K
Capitalization35.44M
CGEN vs SPHRF Comparison Chart in %
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. SPHRF commentary
Sep 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and SPHRF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2025
Stock price -- (CGEN: $1.43 vs. SPHRF: $0.10)
Brand notoriety: CGEN and SPHRF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 51% vs. SPHRF: 114%
Market capitalization -- CGEN: $132.33M vs. SPHRF: $35.44M
CGEN [@Biotechnology] is valued at $132.33M. SPHRF’s [@Biotechnology] market capitalization is $35.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.77B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileSPHRF’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • SPHRF’s FA Score: 0 green, 5 red.
According to our system of comparison, SPHRF is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish while SPHRF’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 4 bullish, 4 bearish.
  • SPHRF’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, SPHRF is a better buy in the short-term than CGEN.

Price Growth

CGEN (@Biotechnology) experienced а -2.72% price change this week, while SPHRF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.28%. For the same industry, the average monthly price growth was +7.11%, and the average quarterly price growth was +29.28%.

Reported Earning Dates

CGEN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($132M) has a higher market cap than SPHRF($35.4M). SPHRF YTD gains are higher at: 33.970 vs. CGEN (-6.536). SPHRF has higher annual earnings (EBITDA): -13.7M vs. CGEN (-19.81M). CGEN has higher revenues than SPHRF: CGEN (22.1M) vs SPHRF (2.98M).
CGENSPHRFCGEN / SPHRF
Capitalization132M35.4M373%
EBITDA-19.81M-13.7M145%
Gain YTD-6.53633.970-19%
P/E Ratio64.00N/A-
Revenue22.1M2.98M742%
Total Cash93.9MN/A-
Total Debt2.97MN/A-
FUNDAMENTALS RATINGS
CGEN vs SPHRF: Fundamental Ratings
CGEN
SPHRF
OUTLOOK RATING
1..100
1042
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
8237
P/E GROWTH RATING
1..100
24100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHRF's Valuation (36) in the null industry is somewhat better than the same rating for CGEN (74) in the Biotechnology industry. This means that SPHRF’s stock grew somewhat faster than CGEN’s over the last 12 months.

SPHRF's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that SPHRF’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (96) in the Biotechnology industry is in the same range as SPHRF (97) in the null industry. This means that CGEN’s stock grew similarly to SPHRF’s over the last 12 months.

SPHRF's Price Growth Rating (37) in the null industry is somewhat better than the same rating for CGEN (82) in the Biotechnology industry. This means that SPHRF’s stock grew somewhat faster than CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for SPHRF (100) in the null industry. This means that CGEN’s stock grew significantly faster than SPHRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENSPHRF
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
45%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
39%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
35%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 23 days ago
43%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARAT0.02N/A
N/A
Arax Holdings Corp.
MDIBF23.05N/A
N/A
MedioBanca SpA
RFNDF1.28N/A
N/A
Rural Funds Group Stapled Securities
SQCF15.75N/A
N/A
Susquehanna Community Financial, Inc.
UMICF15.10-0.15
-0.98%
Umicore SA

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
N/A
NURPF - CGEN
46%
Loosely correlated
+0.04%
BDTX - CGEN
44%
Loosely correlated
+3.21%
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
+2.33%
ROIV - CGEN
40%
Loosely correlated
+1.53%
More

SPHRF and

Correlation & Price change

A.I.dvisor tells us that SPHRF and CGEN have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRF and CGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRF
1D Price
Change %
SPHRF100%
N/A
CGEN - SPHRF
26%
Poorly correlated
N/A
SPHRY - SPHRF
25%
Poorly correlated
N/A
NURPF - SPHRF
23%
Poorly correlated
+0.04%
SOLTF - SPHRF
23%
Poorly correlated
N/A
ASPHF - SPHRF
22%
Poorly correlated
N/A
More